SEC Tracker
Get the app

Cogent Biosciences COGT

Cogent Biosciences reports Q3 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash balance of $791.1 million expected to fund operations into late 2028
  2. R&D expenses increased to $75.1 million in Q3 2026 from $69.0 million in Q3 2025
  3. Net loss was $111.4 million in Q3 2026 compared to $80.9 million in Q3 2025

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Cogent Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. uniQure QURE public float $765M, Jun 30, 2025
  2. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  3. Pacira BioSciences PCRX public float $758M, Jun 30, 2025
  4. Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
  5. Nurix Therapeutics NRIX public float $808M, May 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.